Antimicrobial Stewardship in the Intensive Care Unit: The Role of Biomarkers, Pharmacokinetics, and Pharmacodynamics

[1]  Mohd Shahnaz Hasan,et al.  Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study , 2020, Intensive Care Medicine.

[2]  A. Gayet-Ageron,et al.  Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. , 2020, JAMA.

[3]  D. Marriott,et al.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# , 2020, Intensive Care Medicine.

[4]  E. Colosimo,et al.  Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers , 2020, Critical Care.

[5]  R. Bellomo,et al.  The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: Data from the multinational SMARRT Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  P. Póvoa,et al.  New biomarkers for respiratory infections. , 2020, Current opinion in pulmonary medicine.

[7]  J. D. De Waele,et al.  Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions—a viewpoint of experts , 2020, Intensive Care Medicine.

[8]  Sanmarié Schlebusch,et al.  Antimicrobial-associated harm in critical care: a narrative review , 2020, Intensive Care Medicine.

[9]  S. Polinder,et al.  The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial , 2020, BMC infectious diseases.

[10]  D. Musher,et al.  Procalcitonin to distinguish viral from bacterial pneumonia: A systematic review and meta-analysis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Rello,et al.  Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP) , 2019, Intensive Care Medicine.

[12]  J. D. De Waele,et al.  A Practical Approach to Clinical Antibiotic Stewardship in the ICU Patient with Severe Infection , 2019, Seminars in Respiratory and Critical Care Medicine.

[13]  Paul T. Williams,et al.  Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit , 2019, Seminars in Respiratory and Critical Care Medicine.

[14]  P. Póvoa,et al.  Biomarkers in Pulmonary Infections , 2019, Clinical Pulmonary Medicine.

[15]  J. Powers,et al.  Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis. , 2019, Chest.

[16]  M. Leone,et al.  Efficacy and safety of antimicrobial de-escalation as a clinical strategy , 2018, Expert review of anti-infective therapy.

[17]  P. Póvoa,et al.  C‐reactive protein and procalcitonin profile in ventilator‐associated lower respiratory infections , 2018, Journal of critical care.

[18]  A. Torres,et al.  Initial Inflammatory Profile in Community‐acquired Pneumonia Depends on Time since Onset of Symptoms , 2018, American journal of respiratory and critical care medicine.

[19]  E. Mylonakis,et al.  Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults , 2018, Antimicrobial Agents and Chemotherapy.

[20]  R. Fowler,et al.  Systematic Review and Meta-Analysis of Procalcitonin-Guidance Versus Usual Care for Antimicrobial Management in Critically Ill Patients: Focus on Subgroups Based on Antibiotic Initiation, Cessation, or Mixed Strategies* , 2018, Critical care medicine.

[21]  György J. Simon,et al.  Delay Within the 3-Hour Surviving Sepsis Campaign Guideline on Mortality for Patients With Severe Sepsis and Septic Shock* , 2018, Critical care medicine.

[22]  A. Walker,et al.  Overview of systematic reviews assessing the evidence for shorter versus longer duration antibiotic treatment for bacterial infections in secondary care , 2018, PloS one.

[23]  Maureen G Campion,et al.  Antibiotic Use in the Intensive Care Unit: Optimization and De-Escalation , 2018, Journal of intensive care medicine.

[24]  J. Turnidge,et al.  MIC-based dose adjustment: facts and fables , 2018, The Journal of antimicrobial chemotherapy.

[25]  P. Póvoa,et al.  Biomarker-guided antibiotic therapy-strengths and limitations. , 2017, Annals of translational medicine.

[26]  S. Mahmoud,et al.  Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing , 2017, Pharmaceutics.

[27]  R. Wunderink,et al.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia , 2017, European Respiratory Journal.

[28]  R. Bellomo,et al.  Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. , 2017, International journal of antimicrobial agents.

[29]  W. Self,et al.  Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Alan E. Jones,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.

[31]  Hans Weda,et al.  Exhaled Breath Metabolomics for the Diagnosis of Pneumonia in Intubated and Mechanically-Ventilated Intensive Care Unit (ICU)-Patients , 2017, International journal of molecular sciences.

[32]  D. Heyland,et al.  Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial. , 2016, JAMA internal medicine.

[33]  Margaret A Dudeck,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014 , 2016, Infection Control & Hospital Epidemiology.

[34]  Tom Dormans,et al.  Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. , 2016, The Lancet. Infectious diseases.

[35]  J. Vincent,et al.  New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients , 2016, Antimicrobial Agents and Chemotherapy.

[36]  J. Timsit,et al.  A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  F. Taccone,et al.  Therapeutic drug monitoring of anti-infective agents in critically ill patients , 2016, Expert review of clinical pharmacology.

[38]  P. Póvoa,et al.  Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study , 2016, Annals of Intensive Care.

[39]  T. van der Poll,et al.  Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis. , 2016, JAMA.

[40]  B. Gadeyne,et al.  Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study , 2016, Intensive Care Medicine.

[41]  J. Timsit,et al.  The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. , 2015, The Journal of antimicrobial chemotherapy.

[42]  J. Garnacho-Montero,et al.  Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality , 2015, Critical Care.

[43]  J. Chastre,et al.  Antibiotic stewardship in the intensive care unit , 2014, Critical Care.

[44]  K. Baumstarck,et al.  De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial , 2014, Intensive Care Medicine.

[45]  M. Roberts,et al.  An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. , 2014, The Journal of antimicrobial chemotherapy.

[46]  J. Rello,et al.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  V. Nobre,et al.  Procalcitonin Versus C-Reactive Protein for Guiding Antibiotic Therapy in Sepsis: A Randomized Trial* , 2013, Critical care medicine.

[48]  L. Leibovici,et al.  Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. , 2013, The Journal of antimicrobial chemotherapy.

[49]  N. Roche,et al.  Role of biomarkers in the management of antibiotic therapy: an expert panel review: I – currently available biomarkers for clinical use in acute infections , 2013, Annals of Intensive Care.

[50]  Peter J. Sterk,et al.  Volatile Metabolites of Pathogens: A Systematic Review , 2013, PLoS pathogens.

[51]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[52]  F. Barbier,et al.  Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients , 2013, Antimicrobial Agents and Chemotherapy.

[53]  Arjun Srinivasan,et al.  Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010 , 2013, Infection Control & Hospital Epidemiology.

[54]  P. Marik,et al.  Narrative Review , 2012, Journal of intensive care medicine.

[55]  P. Viale,et al.  Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach , 2012, Antimicrobial Agents and Chemotherapy.

[56]  E. Larson,et al.  Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  D. Ledoux,et al.  Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients* , 2012, Critical care medicine.

[58]  P. Póvoa,et al.  Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review , 2012, Annals of Intensive Care.

[59]  J. Roberts,et al.  Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. , 2012, Chest.

[60]  Lígia Sarmet Cunha Farah Rabello,et al.  Novos marcadores biológicos na pneumonia comunitária grave , 2011 .

[61]  J. Gonçalves-Pereira,et al.  Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams , 2011, Critical care.

[62]  P. L. Petersen,et al.  Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial* , 2011, Critical care medicine.

[63]  P. Póvoa,et al.  C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study , 2011, Critical care.

[64]  M. Kollef,et al.  Antibiotic stewardship in the intensive care unit. , 2011, Seminars in respiratory and critical care medicine.

[65]  S. Shanmugathasan,et al.  Augmented renal clearance in the Intensive Care Unit: an illustrative case series. , 2010, International journal of antimicrobial agents.

[66]  F. Tubach,et al.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.

[67]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[68]  T. S. Wilkinson,et al.  Diagnostic importance of pulmonary interleukin-1β and interleukin-8 in ventilator-associated pneumonia , 2009, Thorax.

[69]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.

[70]  T. Welte,et al.  Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP – Results from the German competence network CAPNETZ , 2009, Respiratory Research.

[71]  Ross Freebairn,et al.  Principles of antibacterial dosing in continuous renal replacement therapy , 2009, Critical care medicine.

[72]  A. Hidrón,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.

[73]  Jerome J. Schentag,et al.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. , 2008, International journal of antimicrobial agents.

[74]  M. Christ-Crain,et al.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[75]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[76]  P. Póvoa,et al.  Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study , 2006, Critical care.

[77]  P. Póvoa,et al.  C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study , 2005, European Respiratory Journal.

[78]  A. MarioCalvo,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. A randomized trial. Chastre J, Wolff M, Fagon JY, Chevret S et al. JAMA 2003; 290: 2588-98 , 2004 .

[79]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[80]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[81]  A. Torres,et al.  The pulmonary physician in critical care • 4: Nosocomial pneumonia , 2002, Thorax.

[82]  J. Rello,et al.  International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-associated Pneumonia. , 2001, Chest.

[83]  M. Kollef.  Optimizing antibiotic therapy in the intensive care unit setting , 2001, Critical care.

[84]  C. Kauffman.  STATE‐OF‐THE‐ART CLINICAL ARTICLE , 1999 .

[85]  F. V. van Tiel,et al.  Indications for antibiotic use in ICU patients: a one-year prospective surveillance. , 1997, The Journal of antimicrobial chemotherapy.

[86]  N. Soni,et al.  C-reactive Protein as a Diagnostic Test of Sepsis in the Critically Ill , 1991, Anaesthesia and intensive care.

[87]  W. Craig,et al.  Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. , 1990, Infection control and hospital epidemiology.

[88]  W. Craig,et al.  Kinetics of antimicrobial activity. , 1986, The Journal of pediatrics.

[89]  P. Shah,et al.  Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus , 1976 .

[90]  J. Waele,et al.  Reducing Antibiotic Use in the ICU: A Time-Based Approach to Rational Antimicrobial Use , 2016 .

[91]  J. Roberts,et al.  The Clinical Relevance of Plasma Protein Binding Changes , 2012, Clinical Pharmacokinetics.

[92]  Aseem Kumar,et al.  Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial , 2012 .

[93]  P. Póvoa,et al.  Novel biomarkers in severe community-acquired pneumonia. , 2011, Revista Brasileira de terapia intensiva.

[94]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[95]  W. Craig,et al.  Killing and regrowth of bacteria in vitro: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[96]  C. Wa,et al.  Killing and regrowth of bacteria in vitro: a review. , 1990 .